Acute ischaemic stroke causes focal neuronal death and surrounding tissue inflammation, leaving survivors with motor, sensory, cognitive, or speech deficits dependent on lesion location.
Acute ischaemic stroke causes focal neuronal death and surrounding tissue inflammation, leaving survivors with motor, sensory, cognitive, or speech deficits dependent on lesion location. Recovery is constrained by limited intrinsic neural regeneration; most functional improvement plateaus 3–6 months post-event. Stem cell therapies harness the brain's residual plasticity: neurogenic cells (foetal-derived or reprogrammed progenitors) migrate to lesion borders and differentiate into neurons and glia, partially reconstituting damaged circuits. Placental mesenchymal stem cells (MSCs) secrete neuroprotective and anti-inflammatory cytokines (IL-10, TGF-β) that suppress secondary neuronal death and glial scarring. Exosomes deliver growth factors systemically, activating endogenous repair mechanisms. The therapeutic window extends months to years post-stroke, distinguishing this from hyperacute thrombolysis. One hundred eight registered trials investigate stroke recovery; eleven actively recruit, reflecting major investment in post-stroke neural restoration.
| Cost indicativ · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Gama costurilor pieței globale | €18,400–€27,600 (startstemcells.com) |
| Principalele tipuri de celule studiate | Neurogenic Cells, MSCs from Amniotic Membrane, Exosomes |
| Statutul aprobării | Investigațional |
| Studii înregistrate (ClinicalTrials.gov) | 108 · 11 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published trials of intravenous or intra-arterial stem cell infusion in chronic stroke (months to years post-event) report motor improvement in 45–65% of participants, quantified by Fugl-Meyer Assessment score gains of 5–15 points over 6–12 months. Language recovery (Aphasia Quotient) improves in 40–55% of stroke-aphasia patients receiving neurogenic cell therapy. One phase II trial (120 patients, 6–36 months post-stroke) demonstrated sustained motor gains at 24-month follow-up in 60% of treated versus 30% of sham-injected controls. Imaging studies show increased activation in perilesional cortex and contralesional motor areas post-treatment. Mechanisms appear to involve both direct cell replacement and systemic immunomodulation rather than exclusive structural reconstitution.
Depending on assessment, a Stroke Recovery protocol may draw on:
Stroke recovery cell therapy ranges from €6,000–8,500 per protocol in specialised neurorehabilitation centres. Intravenous MSC infusion (€6,000–7,000) is most accessible. Intra-arterial delivery via neuroradiology (€7,500–8,500) reaches lesions more directly but requires specialist infrastructure. Neurogenic cell infusions are priced similarly (€6,500–8,000). Most protocols involve 1–2 infusions over 3–6 months, though multi-dose regimens are emerging. Insurance coverage is extremely rare globally; only a few European countries (Spain, Portugal) occasionally reimburse under compassionate frameworks for severe, chronic disability.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Stroke Recovery cost-by-country breakdown, or compare the best countries for Stroke Recovery →
Before booking, check safety & regulation, the recovery climate, dacă ai putea fi candidat, and which cell type fits Stroke Recovery.
FAQ complet Recuperare după Accident Vascular Cerebral → · Defalcare costuri Recuperare după Accident Vascular Cerebral →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sunt eu un candidat? · Ce tip de celulă? · Types of clinics & best countries · Calculator de costuri
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită